OTC · Drug Manufacturers - Specialty & Generic

Avicanna Inc. (AVCNF) Stock

$0.10 +4.32% OTC: AVCNF Healthcare

Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors.

Valuation

MetricValue
Price$0.10
Market Cap$12.15M
P/E Ratio-4.25
P/B Ratio4.00
P/S Ratio0.63
EPS (TTM)$-0.02
52-Week High$0.24
52-Week Low$0.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-116.09%
ROA-16.26%
ROCE-25.02%
Gross Margin51.34%
Operating Margin-12.95%
Net Margin-13.90%
Debt/Equity0.00
Current Ratio0.96

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$4.0M$17.0M$25.0M$25.0M
Operating Profit$-11.0M$-11.0M$-8.0M$-5.0M$-3.0M
Net Profit$-17.0M$-15.0M$-9.0M$-4.0M$-3.0M
EPS$-0.41$-0.25$-0.10$-0.04$-0.02
Op Margin-331.4%-261.4%-47.2%-18.4%-10.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$22.0M$18.0M$22.0M$20.0M$21.0M
Total Liabilities$15.0M$14.0M$14.0M$10.0M$10.0M
Cash$0$1.0M$0$0$0
Borrowings$2.0M$3.0M$2.0M$0$0

Latest News

Avicanna Launching Rapid Onset Medical Cannabis Portfolio in Canada MT Newswires · Jul 16, 2026 Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio GlobeNewswire · Jul 16, 2026 Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer GlobeNewswire · Jun 30, 2026 Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare GlobeNewswire · Jun 15, 2026 Avicanna Announces Closing of Non-Brokered Private Placement GlobeNewswire · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-7.0M$-1.0M$-3.0M$-1.0M
Investing Cash Flow$0$1.0M$-4.0M$-1.0M$-1.0M
Financing Cash Flow$0$1.0M$1.0M$0$0
Net Cash Flow$-1.0M$1.0M$-1.0M$0$0
Free Cash Flow$-12.0M$-8.0M$-2.0M$-3.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.09
EV / EBITDA-6.07
FCF Yield-13.75%
Quick Ratio0.49
Interest Coverage-93.39
Return 1Y-55.29%
Return 3Y-60.59%
Return 5Y—

Ownership

Insiders Held22.59%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Hilton Capital Management, LLC.10,0002023-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Avicanna Inc.

Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatments for lung inflammation associated with COVID-19. Incorporated in 2016, Avicanna Inc. is headquartered in Toronto, Canada.

Avicanna Inc. is headquartered in CA.

Avicanna Inc. (AVCNF) stock trades at $0.10 with a market capitalization of $12.15M. The stock is valued at a price-to-earnings (P/E) ratio of -4.25, price-to-book of 4.00, price-to-sales of 0.63. Over the past 52 weeks the stock has ranged between $0.07 and $0.24, and currently trades 58.3% below its 52-week high.

On profitability, Avicanna Inc. generates a return on equity (ROE) of -116.09%, return on capital employed of -25.02%, an operating margin of -12.95%, a net profit margin of -13.90%.

Official website: www.avicanna.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides